Caribou Biosciences Reports Positive CRISPR Genome-Editing Results, Stock Surges 17.56% on Monday

Caribou Biosciences Inc. (NASDAQ:CRBU) stock surged 17.56% on Monday after the CRISPR genome-editing biopharmaceutical company shared preliminary results from its ongoing ANTLER phase 1 trial of vispacabtagene regedleucel, an allogeneic anti-CD19 CAR-T cell therapy, for relapsed or refractory B-cell non-Hodgkin lymphoma. The therapy achieved a complete response in 64% of patients, with an overall response rate of 82% and a one-year progression-free survival rate of 51%. Caribou plans to conduct a randomized, controlled trial in second-line large B-cell lymphoma patients, and is advancing its CB-011 program for relapsed or refractory multiple myeloma.